ទំព័រដើម › មហារីកសួត › អូរេហ្គោន › Portland
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកសួត នៅក្នុង Portland, OR
ការសិក្សាចំនួន 26 សម្រាប់ មហារីកសួត កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Portland (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Oregon Health & Science University (OHSU), Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · ឆ្ងាយ 12 ម៉ាយ
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Portland
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Oregon Health and Science University ( Site 0052), Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwest Cancer Specialists, P.C., Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Providence Portland Medical Center, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Oregon Health and Science University, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Providence Portland Medical Center, Portland
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
កំពុងជ្រើសរើសដំណាក់កាល 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- និង 2 ទៀត
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- និង 2 ទៀត
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- និង 1 ទៀត
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · ឆ្ងាយ 12 ម៉ាយ
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Portland
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Oregon Health & Science University, Portland
ការសាកល្បងសម្រាប់ មហារីកសួត នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 78
- Boston, MAការសិក្សា 62
- New York City, NYការសិក្សា 60
- Los Angeles, CAការសិក្សា 45
- Washington, DCការសិក្សា 41
- Arlington, VAការសិក្សា 41
- Chicago, ILការសិក្សា 41
- Nashville, TNការសិក្សា 40
- Baltimore, MDការសិក្សា 40
- St. Louis, MOការសិក្សា 39
- Columbus, OHការសិក្សា 37
- Philadelphia, PAការសិក្សា 36
ការសិក្សាផ្សេងទៀតនៅក្នុង Portland
- Non-Small Cell Lung Cancerការសិក្សា 46
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 34
- មហារីកតូចការសិក្សា 33
- មហារីកទ្រូងការសិក្សា 33
- មហារីកដែលរីករាលដាលការសិក្សា 29
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 28
- មហារីកស៊ុតការសិក្សា 27
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 25
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 24
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 19
- មហារីកតំបក់ការសិក្សា 19
- បេះដូងខ្សោយការសិក្សា 17
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។